This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Novel Screening Strategies for Scleroderma PAH

This study is currently recruiting participants.
See Contacts and Locations
Verified September 2017 by Scott Visovatti, MD, University of Michigan
Information provided by (Responsible Party):
Scott Visovatti, MD, University of Michigan Identifier:
First received: October 8, 2013
Last updated: September 17, 2017
Last verified: September 2017
Patients with scleroderma can develop heart failure due to high blood pressure in the lungs (a condition called pulmonary arterial hypertension). It is important to find pulmonary arterial hypertension early, so that it can be treated before heart failure develops. However, the tests that we now use to find the earliest form of this disease in scleroderma patients are not good enough. This study will examine whether tests performed during exercise can improve our ability to find early pulmonary arterial hypertension. The study will also try to identify genes that are responsible for the development of pulmonary arterial hypertension.

Pulmonary Arterial Hypertension Scleroderma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Resource links provided by NLM:

Further study details as provided by Scott Visovatti, MD, University of Michigan:

Primary Outcome Measures:
  • Development of pulmonary arterial hypertension [ Time Frame: Two years after enrollment. ]

Biospecimen Description:
Blood samples will be drawn at rest and during exercise.

Estimated Enrollment: 200
Study Start Date: October 2013
Estimated Study Completion Date: October 2020
Estimated Primary Completion Date: October 2020 (Final data collection date for primary outcome measure)
Scleroderma and diagnosed PAH
"Low risk" scleroderma
Healthy volunteers
"High risk" scleroderma


Ages Eligible for Study:   30 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Volunteers will be recruited from scleroderma clinics, pulmonary hypertension clinics, and (for healthy volunteers) the Ann Arbor area.

Inclusion Criteria:

  • 30 years or older;
  • diagnosis of limited or diffuse scleroderma (American College of Rheumatology criteria)
  • for the "high risk" group, one of the following features:

    • resting transthoracic echocardiogram showing elevated right-sided pressures within previous 3 months [tricuspid regurgitation (TR) jet >2.8 m/s or evidence of right ventricular dysfunction]
    • pulmonary function testing (PFT) showing abnormal diffusing capacity of carbon monoxide (DLCO) not due to significant interstitial lung disease (DLCO<60% predicted or FVC: DLCO ratio >1.4)

Exclusion Criteria:

  • Pregnancy
  • prior diagnosis of pulmonary hypertension
  • treatment with endothelin receptor antagonists, phosphodiesterase-5 inhibitors, or prostacyclin analogues
  • previous diagnosis of obstructive lung disease or pulmonary thromboembolic disease
  • current smoker
  • significant valvular disease
  • resting echocardiogram showing left ventricular ejection fraction<50% within previous 3 months
  • resting echocardiogram showing significant (greater than Grade I) diastolic dysfunction
  • pulmonary emboli (past or present).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01959815

Contact: Ann Johnson, BSN 866-963-3587

United States, Michigan
University of Michigan Recruiting
Ann Arbor, Michigan, United States, 48109
Contact: Ann Johnson, BSN    866-963-3587   
Principal Investigator: Scott Visovatti, MD         
Sponsors and Collaborators
University of Michigan
  More Information

Responsible Party: Scott Visovatti, MD, Assistant Professor, University of Michigan Identifier: NCT01959815     History of Changes
Other Study ID Numbers: HUM00074818
Study First Received: October 8, 2013
Last Updated: September 17, 2017

Additional relevant MeSH terms:
Familial Primary Pulmonary Hypertension
Scleroderma, Systemic
Scleroderma, Diffuse
Vascular Diseases
Cardiovascular Diseases
Hypertension, Pulmonary
Lung Diseases
Respiratory Tract Diseases
Connective Tissue Diseases
Skin Diseases processed this record on September 21, 2017